Breakthrough therapies still need builders

AI Summary

The article argues that biopharma’s next competitive advantage will depend on the talent and operating systems needed to scale discoveries into therapies. It emphasizes the work of building production and delivery capabilities beyond the initial scientific breakthrough.

The next biopharma advantage will come from the talent and systems that turn discovery into scale.